Refinement & validation of rectal wall dose volume objectives for prostate hypofractionation in 20 fractions

Moore, 2019, The financial impact of hypofractionated radiation for localized prostate cancer in the United States, J Oncol, 8170428 Arcangeli, 2017, Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial, J Clin Oncol, 35, 1891, 10.1200/JCO.2016.70.4189 Dearnaley, 2016, Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, Lancet Oncol, 17, 1047, 10.1016/S1470-2045(16)30102-4 Pollack, 2013, Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer, J Clin Oncol, 31, 3860, 10.1200/JCO.2013.51.1972 de Vries, 2019, Hyprofractionated versus conventionally fractionated radiotherapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multi-centre, open-label, phase 3 HYPRO trial, Int J Radiat Oncol Biol Phys Catton, 2017, Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer, J Clin Oncol, 35, 1884, 10.1200/JCO.2016.71.7397 Lee, 2016, Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer, J Clin Oncol, 34, 2325, 10.1200/JCO.2016.67.0448 Zelefsky, 2008, Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer, Int J Radiat Oncol Biol Phys, 70, 1124, 10.1016/j.ijrobp.2007.11.044 Delobel, 2017, Nomogram to predict rectal toxicity following prostate cancer radiotherapy, PLoS One, 12, 10.1371/journal.pone.0179845 Marzi, 2009, Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer, J Exp Clin Cancer Res, 28, 117, 10.1186/1756-9966-28-117 Brenner, 2002, Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue, Int J Radiat Oncol Biol Phys, 52, 6, 10.1016/S0360-3016(01)02664-5 Wortel, 2016, Late side effects after image guided intensity modulated radiation therapy compared to 3D-conformal radiation therapy for prostate cancer: results from 2 prospective cohorts, Int J Radiat Oncol Biol Phys, 95, 680, 10.1016/j.ijrobp.2016.01.031 Olsson, 2018, A systematic post-QUANTEC review of tolerance doses for late toxicity after prostate cancer radiation therapy, Int J Radiat Oncol Biol Phys, 102, 1514, 10.1016/j.ijrobp.2018.08.015 Hoffman, 2014, Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial, Int J Radiat Oncol Biol Phys, 88, 1074, 10.1016/j.ijrobp.2014.01.015 Landoni, 2016, Predicting toxicity in radiotherapy for prostate cancer, Phys Med, 32, 521, 10.1016/j.ejmp.2016.03.003 Vesprini, 2011, Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy, Int J Radiat Oncol Biol Phys, 81, e415, 10.1016/j.ijrobp.2011.01.024 Thor, 2019, Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415, Radiother Oncol, 135, 19, 10.1016/j.radonc.2019.02.014 Akimoto, 2004, Rectal bleeding after hypofractionated radiotherapy for prostate cancer: correlation between clinical and dosimetric parameters and the incidence of grade 2 or worse rectal bleeding, Int J Radiat Oncol Biol Phys, 60, 1033, 10.1016/j.ijrobp.2004.07.695 Arcangeli, 2007, Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area, Radiother Oncol, 84, 148, 10.1016/j.radonc.2007.06.011 Marzi, 2007, Relationships between rectal wall dose-volume constraints and radiobiologic indices of toxicity for patients with prostate cancer, Int J Radiat Oncol Biol Phys, 68, 41, 10.1016/j.ijrobp.2006.12.003 Fiorino, 2002, Rectum contouring variability in patients treated for prostate cancer: impact on rectum dose-volume histograms and normal tissue complication probability, Radiother Oncol, 63, 249, 10.1016/S0167-8140(01)00469-8 Tucker, 2004, Dose-volume response analyses of late rectal bleeding after radiotherapy for prostate cancer, Int J Radiat Oncol Biol Phys, 59, 353, 10.1016/j.ijrobp.2003.12.033 Fiorino, 2002, Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions, Radiother Oncol, 64, 1, 10.1016/S0167-8140(02)00147-0 Thor, 2018, Inter-institutional analysis demonstrates the importance of lower than previously anticipated dose regions to prevent late rectal bleeding following prostate radiotherapy, Radiother Oncol, 127, 88, 10.1016/j.radonc.2018.02.020 Luxton, 2004, Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate, Int J Radiat Oncol Biol Phys, 59, 267, 10.1016/j.ijrobp.2004.01.024 Troeller, 2015, Comparison and limitations of DVH-based NTCP models derived from 3D-CRT and IMRT data for prediction of gastrointestinal toxicities in prostate cancer patients by using propensity score matched pair analysis, Int J Radiat Oncol Biol Phys, 91, 435, 10.1016/j.ijrobp.2014.09.046 Morgan, 2018, Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline, J Clin Oncol, 10.1200/JCO.18.01097 Martin, 2013, Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (A TROG-OCOG Intergroup Project), Radiother Oncol, 107, 333, 10.1016/j.radonc.2013.05.015 Fiorino, 2009, Dose-volume effects for normal tissues in external radiotherapy: pelvis, Radiother Oncol, 93, 153, 10.1016/j.radonc.2009.08.004 Langrand-Escure, 2018, Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: the French genito-urinary group (GETUG) recommendations, CancerRadiother, 22, 193, 10.1016/j.canrad.2017.11.004 Pryor, 2018, Moderate hypofractionation for prostate cancer: A user's guide, J Med Imaging Radiat Oncol, 62, 232, 10.1111/1754-9485.12703 Wheldon, 1998, The linear-quadratic transformation of dose-volume histograms in fractionated radiotherapy, Radiother Oncol, 46, 285, 10.1016/S0167-8140(97)00162-X Sanguineti, 2016, Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study, Int J Radiat Oncol Biol Phys, 96, 304, 10.1016/j.ijrobp.2016.05.017 Michalski, 2010, Radiation dose-volume effects in radiation-induced rectal injury, Int J Radiat Oncol Biol Phys, 76, S123, 10.1016/j.ijrobp.2009.03.078 Diaz, 1994, Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer, Int J Radiat Oncol Biol Phys, 30, 323, 10.1016/0360-3016(94)90011-6 Kestin, 2002, Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume?, Int J Radiat Oncol Biol Phys, 54, 686, 10.1016/S0360-3016(02)03011-0 Gardner, 2002, Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer, J Urol, 167, 123, 10.1016/S0022-5347(05)65395-5 Allen, 2005, The evaluation of rectal bleeding in adults. A cost-effectiveness analysis comparing four diagnostic strategies, J Gen Intern Med, 20, 81, 10.1111/j.1525-1497.2005.40077.x Fiorino, 2008, Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study, Int J Radiat Oncol Biol Phys, 70, 1130, 10.1016/j.ijrobp.2007.07.2354 Fiorino, 2003, Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer, Int J Radiat Oncol Biol Phys, 57, 953, 10.1016/S0360-3016(03)00665-5 Shelley, 2017, Delivered dose can be a better predictor of rectal toxicity than planned dose in prostate radiotherapy, Radiother Oncol, 123, 466, 10.1016/j.radonc.2017.04.008 Landoni, 2006, A study of the effect of setup errors and organ motion on prostate cancer treatment with IMRT, Int J Radiat Oncol Biol Phys, 65, 587, 10.1016/j.ijrobp.2006.01.021 Varela, 2009, Faecal DNA and calprotectin as biomarkers of acute intestinal toxicity in patients undergoing pelvic radiotherapy, Aliment Pharmacol Ther, 30, 175, 10.1111/j.1365-2036.2009.04019.x Valdagni, 2009, To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy, Int J Radiat Oncol Biol Phys, 74, 1431, 10.1016/j.ijrobp.2008.10.021